Paul Balderes
Tri-Institutional Therapeutics Discovery Institute(US)
Publications by Year
Research Areas
Monoclonal and Polyclonal Antibodies Research, Liver physiology and pathology, Phagocytosis and Immune Regulation, Chronic Myeloid Leukemia Treatments, HER2/EGFR in Cancer Research
Most-Cited Works
- → A Fully Human Recombinant IgG-like Bispecific Antibody to Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor for Enhanced Antitumor Activity(2005)180 cited
- → Anti-Vascular Endothelial Growth Factor Receptor-1 Antagonist Antibody as a Therapeutic Agent for Cancer(2006)150 cited
- → Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Human Recombinant Bispecific Antibody(2004)125 cited
- → Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells(2010)122 cited
- → Therapeutic Implications of a Human Neutralizing Antibody to the Macrophage-Stimulating Protein Receptor Tyrosine Kinase (RON), a c-MET Family Member(2006)120 cited
- → Targeting the platelet-derived growth factor receptor α with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: Implications as a potential therapeutic target(2005)119 cited
- → Neuropeptide regulation of non-redundant ILC2 responses at barrier surfaces(2022)112 cited
- → Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2(2006)89 cited
- → Identification of a transiently exposed VE-cadherin epitope that allows for specific targeting of an antibody to the tumor neovasculature(2005)89 cited
- → IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab(2010)76 cited